SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression In AML Xenograft Models
Apr 17th 2008Drug InformationClinical Trials
SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, announced as part of a series of presentations at the 2008 AACR Annual Meeting that that it has identified a lead PIM kinase inhibitor, SGI-1776, that causes tumor regression in acute myologenous leukemia (AML) xenograft models (Abstract No. 4974).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
